How much weight do people lose on semaglutide 2.4 mg?

What does 15% weight loss actually mean in practice?

A 15% reduction sounds like a statistic, but the real-world scale is easier to feel when you attach it to numbers. Someone starting at 100 kg would, on average in the STEP 1 trial, have lost around 15 kg by week 68. At 120 kg, that's roughly 18 kg. These are averages across nearly 2,000 participants, which means some people lost considerably more and some lost less, the distribution is wide. The trial also reported that around 69% of participants achieved at least 10% body-weight loss, and roughly one in three reached 20% or more at the highest dose.

That spread matters. Trial averages answer the question "how much do people lose on semaglutide 2.4 mg" at a population level, but your prescriber looks at you as an individual: your starting BMI, your metabolic history, any other medicines you take, and how you've responded to earlier doses. The relationship between semaglutide dose and weight loss isn't linear, most people see the meaningful shift once they reach the 1.7 mg and 2.4 mg stages, after the earlier steps have settled their system.

One other thing the headline figure doesn't show: participants in STEP 1 also received dietary support and activity guidance alongside the medicine. Weight-loss medicines work alongside behaviour, not instead of it.

Does everyone end up at 2.4 mg, and what if the titration is slower?

Not everyone reaches 2.4 mg at the same pace, and some people stay at a lower dose because of tolerability. The standard Wegovy titration runs 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg, spending roughly four weeks at each level. If nausea or other gastrointestinal effects are significant, a prescriber may slow the climb. That's normal and clinically appropriate, pushing through tolerance problems tends to cause people to stop altogether, which achieves nothing.

The full Wegovy dose schedule and what each stage does is worth reading if you're comparing weeks-to-results across different starting points. People who spend longer at lower doses often catch up by the end of a treatment course once they reach maintenance, though outcomes vary. If you're curious about how the very first dose compares, the page on whether the 0.25 mg dose does anything covers that directly.

A note on timing that's easy to overlook: if you're ordering around a bank holiday or planning to start in December, the four-to-five month period to reach full maintenance means your most active weight-loss phase may fall mid-winter or early spring. Some people plan their start date around that, others don't, but it's worth factoring in.

How does 2.4 mg compare to the newer 7.2 mg dose and to tirzepatide?

This is one of the most common questions our prescribers field. The MHRA approved a 7.2 mg semaglutide maintenance dose in January 2026, with a dedicated single-dose pen following in April 2026. Early trial data for that higher dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results significantly. If you're looking at the 2.4 mg evidence in more detail alongside the newer dose, the difference in average outcomes is meaningful for some people and less relevant for others depending on how they respond to the lower dose.

For context on what tirzepatide trials showed (and how the two medicines differ mechanically) the weight-loss treatment overview gives a balanced comparison. The short version: semaglutide activates one gut-hormone receptor (GLP-1), while tirzepatide activates two (GLP-1 and GIP). Whether that distinction matters for a specific person is a clinical question. NICE's appraisal of both medicines notes that indirect comparisons favour tirzepatide at population level, but the recommendation in NICE TA875 is clear that semaglutide 2.4 mg is effective and recommended for appropriate adults.

What affects how much weight someone actually loses on this dose?

Several things beyond the medicine itself shape outcomes. Protein adequacy matters, appetite suppression can reduce total intake to a point where muscle mass is at risk if protein is proportionally crowded out. Keeping active, particularly with resistance exercise, helps preserve lean mass during weight loss. Hydration is worth paying attention to because reduced appetite can also reduce fluid intake. None of this is about willpower; it's about getting the conditions right so the medicine can do its job.

There's also the question of what NICE calls a 5% weight-loss threshold at six months on the maintenance dose. If someone hasn't achieved at least that, their prescriber is guided to review whether continuing is appropriate. This built-in clinical checkpoint is part of why treatment involves ongoing review, not a single prescription that runs indefinitely. The process for accessing Wegovy through a regulated UK pharmacy includes exactly that kind of repeat clinical assessment before every supply. At nume, that review is carried out by a named GPhC-registered prescriber, and you can read more about our clinical approach on the about us page.

If you'd like to talk through whether Wegovy is right for your situation, start your free consultation and our prescribers will review your details the same day.